Premarket Notification RS Medical RS2mi (Rev 2)

ۍ ب

# 510(k) SUMMARY RS2mi family May 15, 2002

This summary is provided in accordance with the Safe Medical Devices Act of 1990 (SMDA). The information provided in the 510(k), premarket notification was in accordance with 21 CFR 807.87.

### 1. Applicant, Official Correspondent and Owner of 510(k)

RS Medical, Inc. 14401 SE First St. Vancouver, WA 98684-6981

Attn: Mike McGraw, Vice President, Product Development Telephone: (360) 896-2503 Fax: (306) 896-2566

# Submitter of 510(k) and Third Party Reviewer

Underwriters Laboratories Inc. 2600 NW Lake Road Camas, WA 98607-8542 Telephone: (360) 817-5515 Fax: (360) 817-6133

### 2. Name of Device

Trade/Proprietary Name: RS2mi Muscle Stimulator family

Common/Usual Name: Muscle and Interferential Current Stimulator

Classification Name: 21 CFR 890.5850 "Powered Muscle Stimulator", Class II.

# 3. Legally Market Predicate Devices

The RS2mi family is substantially equivalent to its legally marketed predecessor the RS-4M Plus (K000114) muscle stimulator.

Premarket Notification RS Medical RS2mi (Rev 2)

## 4. Indications for Use

#### Muscle Stimulation, Interferential and Non-Interferential Modality

- Relax muscle spasms
- Prevent or retard disuse atrophy
- Maintain or increase range of motion
- Increase local blood circulation
- Re-educate muscle
- Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis

### Pain Relief, Interferential Current Modality

- Relieve acute pain
- Relieve and manage chronic pain

# 5. Device Description and Substantial Equivalence

The RS2mi device family consists of a hardware/software system that can be setup as one of four devices: an RS2m which is a pulse mode muscle stimulator only, an RS2i which is an interferential stimulator only, an RS2c which can act as either a pulse mode muscle stimulator or an interferential stimulator, or an RS2s which acts as a sequential stimulator by first providing an interferential treatment segment followed by a pulse mode muscle stimulation segment. The software system is setup to emulate one of these four devices and the device faceplate is setup to indicate to the user the features of that device only. To provide flexibility, the faceplates can be interchanged by RS Medical to create the type of device needed in the marketplace. Throughout this document the name RS2mi is used to indicate this 'family' of four separate devices.

The RS4M+ incorporates all of these features in one unit, the primary difference is that the predicate device has 4 channels, while the RS2mi has only 2 channels

The RS2mi device family, like a number of legally marketed predicate devices, incorporates traditional muscle stimulation and interferential current stimulation modalities into one unit. Only one modality may be operated at a time. The RS2mi is housed in a plastic enclosure. The front of the enclosure houses LED patient indicators. The accessories provided with the RS2mi include the output cables, the electrode pads, and the AC Charging Adapter.

Both the RS4M+ and the RS2mi use the same materials and texture for the enclosure. Only the enclosure color (TBD) is different. The RS4M+ uses a 2-line LCD Patient Indicator Display. The RS2mi uses LEDs. The RS2mi is designed to use the same output cables, electrode pads, and the AC Charging Adapter as the predicate device Premarket Notification RS Medical RS2mi (Rev 2)

.

The RS2mi pulse mode muscle stimulation modality operates at a specified 57.5 volts peak (+/-10% into a 500 ohm load) and 115 mA peak (+/-10% into a 500 ohm load) with a maximum pulse width of 415  $\mu$ Sec.( +/-10%) and a cycle frequency of 71 Hz(+/-5%). The pulses are bi-phasic. Intensity levels are controlled via pulse width while maintaining the pulse voltage within the specified peak. The waveform includes an on/off ramp, which slowly increases the pulse width to the desired setting.

The RS4M+ is the same.

The RS2mi interferential modality operates at a specified maximum of 100 mA peak (+/-10% into a 500 ohm load). The carrier and interferential signals are simulated sine wave symmetric, balanced outputs with zero net charge. The interferential modality can operate in a true interferential mode (4 pad mode) or the signals can be pre-mixed and only the pre-mixed signals sent to the patient (2 pad mode). The interference signal frequency can be fixed (Continuous) or varied based on three selections (Variable).

The RS4M+ is the same.



**Public Health Service** 

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUN 1 3 2002

Mrs. Molly Bettger RS Medical C/O: Underwriters Laboratories, Inc. 2600 NW Lake Road Camas, WA 98607-8542

Re: K021763

Trade/Device Name: RS2mi muscle stimulator family, models: RS2m, RS2i, RS2c, and RS2s Regulation Number: 21 CFR 890.5850 Regulation Name: Powered muscle stimulator Regulatory Class: Class II Product Code: 89 IPF and 84 LIH Dated: May 20, 2002

Dear Mrs. Bettger:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

#### Page 2 - Mrs. Bettger

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for <u>in vitro</u> diagnostic devices), please contact the Office of Compliance at (301) 594-. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Premarket Notification RS Medical RS-2mi

KOZ1763

# **Premarket Notification**

# **Indications For Use**

Device Name: RS2mi Muscle Stimulator family

#### **Indications For Use:**

# Muscle Stimulation, Interferential and Non-Interferential Modality

- Relax muscle spasms
- Prevent or retard disuse atrophy
- Maintain or increase range of motion
- Increase local blood circulation
- Re-educate muscle
- Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis

#### Pain Relief, Interferential Current Modality

- Relieve acute pain
- Relieve and manage chronic pain

#### (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use: (Per 21 CFR 801.109)

}

(Optional Format 1-2-96)

X OR

Over-The-Counter:

(Division Sign-Off) Division of General, Restorative and Neurological Devices

510(k) Number \_\_\_\_K021763\_\_\_\_

- 8 -